At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 197 enrolled
Drug / intervention
CP-690,550 +3 moredrug
Likely dose
CP-690,550 2 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2B, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Trial Evaluating The Efficacy And Safety Of Dose Regimens With Oral CP-690,550 In The Treatment Of Subjects With Moderate To Severe Chronic Plaque Psoriasis
In Brief
A Phase 2 clinical trial evaluating CP-690,550 and Placebo for Psoriasis. Completed, enrolled 197 participants across 44 sites in 2 countries.
Detailed Summary
The purpose of this study is to determine the effectiveness and safety, over 12 weeks, of 3 dosing regimens of CP-690,550 for the treatment of adults with moderate to severe chronic plaque psoriasis.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPsoriasis
CountriesCanada, United States
Collaborators--
Timeline
Phase 2CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedMay 2008
Enrollment StartJul 2008
Primary CompletionAug 2009
TodayJul 2026
First PostedMay 15, 2008
Enrollment StartJul 1, 2008
Primary CompletionAug 1, 2009
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 18.1 years ago
Interventions
CP-690,550drug
tablets, 2 mg BID for 12 weeks
CP-690,550drug
tablets, 5 mg BID for 12 weeks
CP-690,550drug
tablets, 15 mg BID for 12 weeks
Placebodrug
tablets, BID for 12 weeks